Fara

Sikorsky S-97 RAIDER Demonstrates Agility at the X During Future Vertical Lift Flight Demonstrations at Redstone Arsenal

Retrieved on: 
Thursday, April 15, 2021
Rotorcraft, Helicopters, Aircraft, Military helicopters, Sikorsky Raider X, Future Vertical Lift, Future Attack Reconnaissance Aircraft, FVL, Lockheed Martin, VTOL, Fara, Future Long-Range Assault Aircraft

The events offered a glimpse at Sikorsky, a Lockheed Martin company\'s bid for the Future Attack Reconnaissance Aircraft (FARA) program, part of the U.S. Army\'s Future Vertical Lift (FVL) effort to revolutionize its aircraft fleet.

Key Points: 
  • The events offered a glimpse at Sikorsky, a Lockheed Martin company\'s bid for the Future Attack Reconnaissance Aircraft (FARA) program, part of the U.S. Army\'s Future Vertical Lift (FVL) effort to revolutionize its aircraft fleet.
  • "This is the first of what we believe will be many times our X2 Future Vertical Lift aircraft will fly at Redstone.
  • This proven, holistic life-cycle approach runs seamlessly throughout the design, development, production, supply chain and sustainment process.
  • "Every time we fly, we are learning something that goes right into RAIDER X and DEFIANT X.

Exicure Announces Agenda for Upcoming Neuroscience Pipeline Update at Virtual R&D Day

Retrieved on: 
Monday, January 4, 2021
Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical trials, Other Health, Neurological disorders, Rare diseases, Friedreich's ataxia, Fara, Ataxia, Neurodegenerative disorders, Friedreich’s Ataxia, SCN9A, CLN3 Batten Disease, Exicure, Inc.

She is a member of the Medical Research Advisory Board for the National Ataxia Foundation and has been a primary investigator for several Friedreichs Ataxia trials.

Key Points: 
  • She is a member of the Medical Research Advisory Board for the National Ataxia Foundation and has been a primary investigator for several Friedreichs Ataxia trials.
  • Jennifer Farmer, MS is the CEO of the Friedreichs Ataxia Research Alliance (FARA).
  • A live webcast will be available in the Events and Presentations section of Exicures website on January 7, 2021 at 09:00 am ET.
  • Exicure is in preclinical development of XCUR-FXN an SNAbased therapeutic candidate, for the treatment of Friedreichs ataxia (FA).

Exicure Provides Neuroscience Pipeline Update at Virtual R&D Day

Retrieved on: 
Monday, December 28, 2020
Research, Infectious diseases, Genetics, Other Health, Biotechnology, General Health, Pharmaceutical, Health, Science, Other Science, Neurological disorders, Rare diseases, Susan Perlman, Fara, Friedreich's ataxia, Ataxia

Exicures Scientific Advisory Board member Dr. Susan Perlman and the CEO of the Friedreichs Ataxia Research Alliance (FARA) Jennifer Farmer, will join Exicures leadership team in discussing the companys progress in Friedreichs Ataxia and its expanding neuroscience pipeline.

Key Points: 
  • Exicures Scientific Advisory Board member Dr. Susan Perlman and the CEO of the Friedreichs Ataxia Research Alliance (FARA) Jennifer Farmer, will join Exicures leadership team in discussing the companys progress in Friedreichs Ataxia and its expanding neuroscience pipeline.
  • She is a member of the Medical Research Advisory Board for the National Ataxia Foundation and has been a primary investigator for several Friedreichs Ataxia trials.
  • Jennifer Farmer, MS is the CEO of the Friedreichs Ataxia Research Alliance (FARA).
  • Exicure is in preclinical development of XCUR-FXN an SNAbased therapeutic candidate, for the treatment of Friedreichs ataxia (FA).

ITT Enidine Selected by Bell for the Bell 360 Invictus Prototype for U.S. Army Future Attack Reconnaissance Aircraft (FARA) Program

Retrieved on: 
Wednesday, December 2, 2020
Technology, Other Manufacturing, Textiles, Steel, Packaging, Engineering, Chemicals, Plastics, Air, Transport, Automotive Manufacturing, Other Technology, Aerospace, Manufacturing, Helicopters, Rotorcraft, Aircraft, Military helicopters, Future Attack Reconnaissance Aircraft, Bell 525 Relentless, Bell 505 Jet Ranger X, Fara, Bell 206, Bell Textron, Bell 360 Invictus

Enidine joins eight other elite aerospace teammates in Bells mission to submit the Bell 360 competitive prototype to the U.S. Armys Future Attack Reconnaissance Aircraft (FARA) program.

Key Points: 
  • Enidine joins eight other elite aerospace teammates in Bells mission to submit the Bell 360 competitive prototype to the U.S. Armys Future Attack Reconnaissance Aircraft (FARA) program.
  • As a teammate in Team Invictus, Enidine will work with Bell to produce passive Liquid Inertia Vibration Eliminator (LIVE) units.
  • Enidine and the rest of Team Invictus are in the first stage of designing and developing the Bell 360 prototype, with the Armys FARA program targeting a first flight for late Calendar Year 2022.
  • Enidine first began providing LIVE units for Bell in the Bell 505 Jet Ranger X and the Bell 525 Relentless commercial aircraft.

Statement On DOJ Decision Related To Al Jazeera Filing Under FARA

Retrieved on: 
Friday, September 18, 2020
Mass media, Television, Fara, Arab culture, Al Jazeera, AJ+

"We disagree with the U.S, Department of Justice (DOJ) decision to require AJ+ to file under FARA.

Key Points: 
  • "We disagree with the U.S, Department of Justice (DOJ) decision to require AJ+ to file under FARA.
  • "Further, the timing of this FARA announcement the day before the UAE formally signed an agreement normalizing relations with Israel is of note.
  • The classification of Al Jazeera under FARA seems wholly political.
  • Calling Al Jazeera a propaganda outlet instead of the independent news organization it is sends exactly the wrong message."

Official Statement by the Qatar-America Institute: Structural & Legal Developments

Retrieved on: 
Friday, June 26, 2020
Gluten-free diet, Quality Assurance International, Fara, Foreign Agent, Foreign Agents Registration Act, 501(c)(3) organization, Food and drink, Organizations, Decades

WASHINGTON, June 26, 2020 /PRNewswire/ -- The Qatar-America Institute (QAI) recently filed documents related to the Foreign Agents Registration Act (FARA).

Key Points: 
  • WASHINGTON, June 26, 2020 /PRNewswire/ -- The Qatar-America Institute (QAI) recently filed documents related to the Foreign Agents Registration Act (FARA).
  • This registration pertained to activities that QAI undertook from October 2017 through October 2019 while QAI was a 501(c)(4) nonprofit organization during the tenure of QAI's founding leadership.
  • After changing its status to a 501(c)(3) nonprofit, QAI underwent a change of leadership and embarked on a new mission in October 2019.
  • The new QAI leadership does not intend to engage in any activities requiring registration under FARA going forward.

The Friedreich’s Ataxia Research Alliance Hires Barbara Tate, Ph.D. as FARA's New Chief Scientific Officer

Retrieved on: 
Wednesday, May 27, 2020
Fara, Ataxia, Nonprofit organization, Organizations, Friedreich's Ataxia Research Alliance, Kyle Bryant, Articles, Health, Autosomal dominant disorders, Rare diseases

DOWNINGTOWN, Pa., May 27, 2020 (GLOBE NEWSWIRE) -- The Board of Directors of the Friedreichs Ataxia Research Alliance (FARA) today announced the hiring of Barbara Tate, Ph.D. to the full-time role of Chief Scientific Officer (CSO).

Key Points: 
  • DOWNINGTOWN, Pa., May 27, 2020 (GLOBE NEWSWIRE) -- The Board of Directors of the Friedreichs Ataxia Research Alliance (FARA) today announced the hiring of Barbara Tate, Ph.D. to the full-time role of Chief Scientific Officer (CSO).
  • FARA is a national, non-profit organization dedicated to the pursuit of scientific research leading to treatments and a cure for Friedreichs ataxia (FA).
  • Dr. Tates responsibilities will include the oversight of all research and drug development activities as well as leading FARAs research staff.
  • The Friedreichs Ataxia Research Alliance (FARA) is a national, public, 501(c)(3), non-profit, tax-exempt organization dedicated to the pursuit of scientific research leading to treatments and a cure for Friedreichs ataxia.

 Exicure Announces First Neurological Development Program in Friedreich’s Ataxia and Expands Scientific Advisory Board

Retrieved on: 
Monday, December 16, 2019
Health, Genetics, Other Health, General Health, Clinical trials, Pharmaceutical, Biotechnology, Neurological disorders, Rare diseases, Friedreich's Ataxia Research Alliance, Trinucleotide repeat disorders, Organ systems, Fara, Friedreich's ataxia, Ataxia, Nikolaus Friedreich, Kyle Bryant, Autosomal dominant disorders, Friedreich’s Ataxia (FA), FARA, Exicure, Inc.

Exicure also announced the expansion of its Scientific Advisory Board.

Key Points: 
  • Exicure also announced the expansion of its Scientific Advisory Board.
  • Over the past year Exicure has developed extensive preclinical data supporting the development of our SNAs for neurological disorders.
  • We are also pleased to add the experience and team from the Friedreichs Ataxia Research Alliance (FARA), added Dr. Giljohann.
  • The Friedreich's Ataxia Research Alliance (FARA) is a 501(c)(3), non-profit, charitable organization dedicated to accelerating research leading to treatments and a cure for Friedreich's ataxia.

The Friedreich’s Ataxia Research Alliance Promotes Jennifer Farmer, MS to Chief Executive Officer

Retrieved on: 
Thursday, December 5, 2019
Neurological disorders, Fara, Organ systems, Rare diseases, Ataxia, Friedreich's ataxia, Friedreich's Ataxia Research Alliance, Kyle Bryant

DOWNINGTOWN, Pa., Dec. 05, 2019 (GLOBE NEWSWIRE) -- The Board of Directors at The Friedreichs Ataxia Research Alliance (FARA) today announced the promotion of Jennifer Farmer, MS to the role of Chief Executive Officer (CEO).

Key Points: 
  • DOWNINGTOWN, Pa., Dec. 05, 2019 (GLOBE NEWSWIRE) -- The Board of Directors at The Friedreichs Ataxia Research Alliance (FARA) today announced the promotion of Jennifer Farmer, MS to the role of Chief Executive Officer (CEO).
  • More than fifteen therapeutic development programs for FA have started in the biopharmaceutical industry during Ms.
  • Farmers time as Executive Director, and she has led the way in ensuring FARA is a model in patient centered research.
  • The Friedreichs Ataxia Research Alliance (FARA) is a national, public, 501(c)(3), non-profit, tax-exempt organization dedicated to the pursuit of scientific research leading to treatments and a cure for Friedreichs ataxia.

Two Louisiana youth honored for volunteerism at national award ceremony in Washington, D.C.

Retrieved on: 
Monday, May 6, 2019
Neurological disorders, Rare diseases, Organ systems, Trinucleotide repeat disorders, Friedreich's Ataxia Research Alliance, Ataxia, Fara, Nikolaus Friedreich, Friedreich's ataxia, Fa, Kyle Bryant, Autosomal dominant disorders

In 2016, Kate was diagnosed with Friedreich's ataxia (FA), an inherited degenerative condition that has no cure or treatments.

Key Points: 
  • In 2016, Kate was diagnosed with Friedreich's ataxia (FA), an inherited degenerative condition that has no cure or treatments.
  • She also wanted to teach people the importance of treating people with disabilities the same as everyone else.
  • While attempting to learn as much as possible about her disease, Kate discovered a national organization, the Friedreich's Ataxia Research Alliance (FARA), dedicated to FA research.
  • For B-roll ofLouisiana's honorees at the 2019 national recognition events, contactPrudential's HaroldBanks at (973) 216-4833 or [email protected].